new_0222_0290|ADGI|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0290|ADGI|1|Adagio Therapeutics Inc Total Current Assets (Quarterly) (USD)|Adagio Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Adagio Therapeutics Inc Inventories (Quarterly) (USD)|Adagio Therapeutics Inc Net PP&E (Quarterly) (USD)|Adagio Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Adagio Therapeutics Inc Total Liabilities (Quarterly) (USD)|Adagio Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Adagio Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Adagio Therapeutics Inc Total Deposits (Quarterly) (USD)|Adagio Therapeutics Inc Book Value (Quarterly) (USD)|Adagio Therapeutics Inc Retained Earnings (Quarterly) (USD)|Adagio Therapeutics Inc Treasury Stock (Quarterly) (USD)|Adagio Therapeutics Inc EV to Revenues|Adagio Therapeutics Inc EV to Earnings|Adagio Therapeutics Inc EV to Free Cash Flow|Adagio Therapeutics Inc EV to Assets (Quarterly)|Adagio Therapeutics Inc PS Ratio|Adagio Therapeutics Inc PE Ratio|Adagio Therapeutics Inc Price to Book Value|Adagio Therapeutics Inc PEG Ratio|Adagio Therapeutics Inc Debt to Equity Ratio|Adagio Therapeutics Inc Dividend Yield|Adagio Therapeutics Inc Shareholder Yield (TTM)|Adagio Therapeutics Inc Percent of Shares Outstanding Short|Adagio Therapeutics Inc Total Receivables (Quarterly) (USD)|Adagio Therapeutics Inc Total Payables (Quarterly) (USD)|Adagio Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Adagio Therapeutics Inc Return on Invested Capital|Adagio Therapeutics Inc Quality Ratio Score|Adagio Therapeutics Inc Momentum Score|Adagio Therapeutics Inc Beta (1Y)|Adagio Therapeutics Inc Sustainable Growth Rate (TTM)|Adagio Therapeutics Inc Institutional Investor Ownership Percentage|Adagio Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Adagio Therapeutics Inc Total Employees (Annual)|Adagio Therapeutics Inc EPS Diluted (Quarterly) (USD)|Adagio Therapeutics Inc SG&A Expense (Quarterly) (USD)|Adagio Therapeutics Inc Shares Outstanding|Adagio Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Adagio Therapeutics Inc Ordinary Shares Number (Quarterly)|Adagio Therapeutics Inc Payout Ratio|Adagio Therapeutics Inc Quick Ratio (Quarterly)|Adagio Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Adagio Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Adagio Therapeutics Inc Effective Tax Rate (TTM)|Adagio Therapeutics Inc Return on Equity|Adagio Therapeutics Inc Net Income (TTM) (USD)|Adagio Therapeutics Inc Revenue (TTM) (USD)|Adagio Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Adagio Therapeutics Inc Revenue (Quarterly) (USD)|Adagio Therapeutics Inc Gross Profit (Quarterly) (USD)|Adagio Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Adagio Therapeutics Inc Net Income (Quarterly) (USD)|Adagio Therapeutics Inc Net Interest Income (Quarterly) (USD)|Adagio Therapeutics Inc Price (USD)|Adagio Therapeutics Inc Total Return Price (USD)|Adagio Therapeutics Inc Enterprise Value (USD)|Adagio Therapeutics Inc 30-Day Average Daily Volume|Adagio Therapeutics Inc 1 Year Price Returns (Daily)|Adagio Therapeutics Inc Short Interest|Adagio Therapeutics Inc PE Ratio (Forward)|Adagio Therapeutics Inc PE Ratio (Forward 1y)|Adagio Therapeutics Inc PS Ratio (Forward)|Adagio Therapeutics Inc PS Ratio (Forward 1y)|Adagio Therapeutics Inc Quarterly EPS Estimates (USD)|Adagio Therapeutics Inc Quarterly Revenue Estimates (USD)|Adagio Therapeutics Inc Quarterly EPS Surprise|Adagio Therapeutics Inc Quarterly Revenue Surprise|Adagio Therapeutics Inc Quarterly Actual EPS (USD)|Adagio Therapeutics Inc Quarterly Actual Revenue (USD)|Adagio Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Adagio Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Adagio Therapeutics Inc Price Target (USD)|Adagio Therapeutics Inc Consensus Recommendation|Adagio Therapeutics Inc Price Target Num Estimates|Adagio Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Adagio Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Adagio Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Adagio Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Adagio Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Adagio Therapeutics Inc Land and Improvements (Quarterly) (USD)|Adagio Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Adagio Therapeutics Inc Other Properties (Quarterly) (USD)|Adagio Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0290|ADGI|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0290|ADGI|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0290|ADGI|5|91.5|91.5||||91.5|91.5|91.5||91.5|91.5|91.5|||||||1.4387755102|||1.44117647059||15.5454545455||91.5|91.5||||||30.6|121.666666667||121.666666667|121.666666667|19.6||91.5|||121.666666667|91.5||||||||121.666666667|121.666666667|121.666666667|1.44117647059|1.44117647059|1.44117647059|1.43925233645||15.5454545455|||1.44117647059|1.44117647059|91.5|91.5|92||92|92|18.2857142857|11.6363636364|9.84615384615|7.11111111111|9.84615384615|18.2857142857|21.3333333333|121.666666667||||||||
new_0222_0290|ADGI|6|2|2||||2|2|2||2|2|2|||||||98|||136||11||2|2||||||5|3||3|3|5||2|||3|2||||||||3|3|3|136|136|136|107||11|||34|34|6|6|1||1|1|7|11|13|18|13|7|6|3||||||||
new_0222_0290|ADGI|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0290|ADGI|202009||||||||||||||||||||||||||||||||||63.24||-0.7591|0.842||||||-0.7591|||||||||-48.008|-48.008|||||||||||||||||||||||||47.166||||||||
new_0222_0290|ADGI|202103|94.874|91.247||||108.53|28.677|79.853||-103.362|-104.019|0.085||||||||||||||11.317|89.707|||||||63.24||-0.61|3.677|||108.0157|||-0.61|||||||||-38.7|-38.7|0.009||||||||||||||||||||||||35.032||||||||
new_0222_0290|ADGI|202106|396.059|392.509||||542.616|37.897|504.719||-144.624|-148.692|||||||||||||0.2678||10.716|0.001||||||31.8342|108.0157|75|-0.4136|7.124|111.2457||108.0157|||-0.4136|||||||||-44.673|-44.673|0.023|33.84|33.84|3372.0455|||297876|||||-0.73||77.3315||-0.1655|||90.8449|47.5|1.5|4|-3.17|-3.63|37.567||||||||
new_0222_0290|ADGI|202109|680.155|666.322||||53.057|53.049|0.008||633.213|-209.067||||||||7.4213|||||1.2825|0.682|17.564|0.005||||||76.4814|61.2971||-0.98|11.052|111.2517||111.2517|||-0.98|-330.905|||-191.756|||||-60.375|-60.375|0.048|42.24|42.24|4032.9498|575605.6667||1426771|||||-0.57||-55.614||-0.887|||148.4949|51.5|1.5|4|-1.73|-3.6|49.366|||||||29.24|47.04
new_0222_0290|ADGI|202112|||||||||||||||||||1.2755|||||6.4907|||||||||79.2709||||||||||||||||||||||7.26|7.26|141.3653|14268448||7221057|||12.8137|1.382|-1.09||||||63.0333|103.1381|10|3|3|-2.185|-2.74||||||||7.18|6.42
new_0222_0290|ADGI|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.55|||||||||||||||||||||
new_0222_0290|ADGI|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.59|||||||||||||||||||||
new_0222_0290|ADGI|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.64|||||||||||||||||||||
new_0222_0290|ADGI|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.58|139.1||||||||||||||||||||